Figure 5 (IMAGE) Impact Journals LLC Caption Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling. Credit 2024 Zhang et al. Usage Restrictions Original Content License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.